Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy

Apatinib is a tyrosine kinase inhibitor and vascular endothelial growth factor receptor 2 (VEGFR-2) targeted drug. A phase I clinical trial showed that this agent has antitumor activity in Chinese patients with metastatic gastric cancer (mGC). The aim of this study was to investigate the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Hanguang, Dong, Junlin, Zhou, Xueliang, Xiong, Juan, Wang, Hua, Zhong, Xiaoming, Cao, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732826/
https://www.ncbi.nlm.nih.gov/pubmed/29262660
http://dx.doi.org/10.18632/oncotarget.21053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732826/
https://www.ncbi.nlm.nih.gov/pubmed/29262660
http://dx.doi.org/10.18632/oncotarget.21053

Ejemplares similares